ClinicalTrials.gg

Program

RB-ADSC

Its studies are mostly in Alzheimer Disease, led by Regeneration Biomedical.

Furthest: phase 2, since Sep 17, 20253 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneration Biomedical32 open or runningphase 2since Sep 17, 2025Dec 1, 2022Sep 2028phase 1 · NCT07373067

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2022First study: phase 1 study in Alzheimer DiseaseFirst studyNCT05667649 · 7 enrolled · United States
  2. Sep 17, 2025Phase 2 study in Alzheimer DiseaseNCT07205601 · 115 planned
  3. Jan 15, 2026Phase 1 study in Alzheimer DiseaseNCT07373067 · 9 planned

Ahead

  1. Sep 2028Primary completion: phase 1 study in Alzheimer DiseaseNCT07373067
  2. Feb 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07205601

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07373067Alzheimer Disease1Not yet recruitingSep 20289
NCT07205601Alzheimer Disease2Not yet recruitingFeb 2029115
NCT05667649Alzheimer Disease · United States1CompletedJun 25, 20267

How it is read

Names in the registry

  • “RB-ADSC”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.